Stephan D Glenn

Title: Innovations of Stephan D Glenn in Antiviral Research

Introduction

Stephan D Glenn is an accomplished inventor based in Weston, FL (US). He has made significant contributions to the field of antiviral research, particularly in the context of coronavirus treatments. His innovative work has led to the development of a patent that addresses critical health challenges.

Latest Patents

Stephan D Glenn holds a patent for "Terameprocol and nordihydroguaiaretic acid (NDGA) derivatives as coronavirus anti-viral agents." This patent highlights the utility of NDGA derivatives, including terameprocol (TMP), as effective antiviral agents for patients infected with or at risk of infection from coronaviruses, including SARS-CoV-2. In vitro studies have demonstrated that coronavirus-infected cells treated with TMP show reduced viral RNA activity. Notably, treatment-related cytotoxicity is not observed at lower concentrations of TMP, making it a promising candidate for therapeutic applications.

Career Highlights

Stephan D Glenn has established himself as a key figure in the pharmaceutical industry. He is currently associated with Erimos Pharmaceuticals, LLC, where he continues to advance his research and development efforts. His work is characterized by a commitment to finding innovative solutions to pressing health issues.

Collaborations

Stephan collaborates with Jeffrey Khoo, contributing to the advancement of antiviral therapies. Their combined expertise enhances the potential for developing effective treatments against viral infections.

Conclusion

Stephan D Glenn's contributions to antiviral research, particularly through his patent on NDGA derivatives, underscore his role as an innovator in the pharmaceutical field. His work holds promise for improving treatment options for patients facing coronavirus infections.